Praluent Pricing: Collaboration With ICER Sets A New Standard
Sanofi/Regeneron reveal plans to lower price of PCSK9 blocker Praluent to match ICER's updated recommendation, following assessment based on new outcomes data. Decision sparks debate across industry and raises questions about setting precedent on pricing for the future.
You may also be interested in...
The drug value assessment organization said it is considering whether or not to move forward with a program to consult pharmaceutical manufacturers on early research, a move that could raise questions about the group's independence.
In an exclusive interview, one of the most direct CEOs in the industry, Regeneron’s Len Schleifer, clarifies his attitude to drug pricing and growing internal innovation.
PCSK9 Inhibitor Labeling Parity Is Within Reach As Praluent And Repatha Strive To Make Commercial Case
Sanofi and Regeneron’s Praluent could draw even with Amgen’s US Repatha in approved FDA indications in 2019. While the injectable PCSK9 inhibitors battle for payers and prescribers, Esperion is readying its oral bempedoic acid to join the lipid-lowering fray – and strategizing towards what could be the first statin intolerance indication.